Too many promising medical technologies stall before they ever reach patients. Not because the science is flawed—because the execution is. Companies fail due to regulatory missteps, weak commercialization strategies, and an inability to build infrastructure.
We acquire these de-risked but stalled medical technologies and build them into enduring businesses...backed by infrastructure, capital, and a team that’s done it before.
We've acquired a precision surgical robotics platform developed over more than a decade of engineering and clinical collaboration.
Built around a cooperative approach to microsurgery, the robotic system was designed to preserve surgeon control while enhancing precision, stability, and dexterity in delicate operating environments. After substantial investment in research, product development, and regulatory advancement, the platform demonstrated the promise, yet never achieved its full commercial potential.
